person · Reporting owner

RAMSAY DAVID A

Disclosed activity across 3 companies

Tapewire entity: 33113
SEC CIK: 0001283292

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
HALOZYME THERAPEUTICS, INC.HALO · Entity 793	EVP, PRESIDENT, DRUG DELIVERY	June 30, 2026	July 02, 2026
Savara IncSVRA · Entity 4900	Director	December 19, 2025	December 19, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

HALOZYME THERAPEUTICS, INC.

Report date June 30, 2026 · Filed July 02, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	4,592	Ending reported balance After 2026-06-30 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-06-30 · Exercise / conversion · Acquired 10,000 · Balance 10,000 Row 2 · 2026-06-30 · Tax withholding · Disposed 5,408 · Balance 4,592 F1: The reported disposition of 5,408 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2026-06-30 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-06-30 · Exercise / conversion · Disposed 10,000 · Balance 0 F2: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. The shares received upon vesting remain subject to a one-year holding period from the vesting date.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	16,232	Reported balance After 2026-07-01 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-07-01 · Grant · Acquired 16,232 · Balance 16,232 F3: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $77.01 · Expires 2036-07-01	Direct	39,823	Reported balance After 2026-07-01 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-07-01 · Grant · Acquired 39,823 · Balance 39,823 F4: This option vests one-fourth on such date and then 1/48th monthly thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: The reported disposition of 5,408 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.

F2: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. The shares received upon vesting remain subject to a one-year holding period from the vesting date.

F3: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter.

F4: This option vests one-fourth on such date and then 1/48th monthly thereafter.

Savara Inc

Report date December 19, 2025 · Filed December 19, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,533,642	Reported balance After 2025-12-19 transaction · row 1 1 source row Row 1 · 2025-12-19 · Sale · Disposed 20,000 · Balance 2,533,642 F1: Represents shares sold to satisfy tax liability upon the vesting of restricted stock units. F2: The price is a weighted average sales price. The sale prices ranged from $6.04 to $6.08. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares sold to satisfy tax liability upon the vesting of restricted stock units.

F2: The price is a weighted average sales price. The sale prices ranged from $6.04 to $6.08. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

LA JOLLA PHARMACEUTICAL CO

Report date August 22, 2022 · Filed August 24, 2022

Section 16 reporting ended · disclosed 2022-08-24. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2022-08-22 transaction · row 1 1 source row Row 1 · 2022-08-22 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $6.23 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.43	Direct	Reported balance After 2022-08-22 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-08-22 · Disposition to issuer · Disposed 18,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.93	Direct	Reported balance After 2022-08-22 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-08-22 · Disposition to issuer · Disposed 12,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.81	Direct	Reported balance After 2022-08-22 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2022-08-22 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option.
Stock Option (Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $4.53	Direct	Reported balance After 2022-08-22 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-08-22 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $6.23 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.

F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 17, 2019 Filed Jun 19, 2019 21:58 UTC	Savara Inc SVRA · Entity 4900	PurchaseCommon Stock	10,000	$2.39	$23,900.00	Disclosure SEC source: 0000899243-19-017457 · doc4.xml · nonDerivative · entry 2 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,570 Read SEC document
December 13, 2018 Filed Dec 14, 2018 21:37 UTC	Savara Inc SVRA · Entity 4900	GrantStock Option (Right to Buy) · Derivative	12,000	$0.00 Strike: $7.33	$0.00	Disclosure SEC source: 0000899243-18-031094 · doc4.xml · derivative · entry 1 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2028-12-13 F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in twelve equal installments on each quarterly anniversary of December 13, 2018, subject to the reporting person's continued service with the Issuer. Read SEC document
June 07, 2017 Filed Jun 9, 2017 14:35 UTC	Savara Inc SVRA · Entity 4900	PurchaseCommon Stock	21,000	$4.75	$99,750.00	Disclosure SEC source: 0000899243-17-015874 · doc4.xml · nonDerivative · entry 1 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,428 Read SEC document
May 25, 2017 Filed May 26, 2017 22:53 UTC	Savara Inc SVRA · Entity 4900	GrantStock Option (Right to Buy) · Derivative	3,750	$0.00 Strike: $5.13	$0.00	Disclosure SEC source: 0000899243-17-014622 · doc4.xml · derivative · entry 1 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires 2027-05-25 F1 · derivative.exercise_date: The option vests and becomes exercisable in six equal monthly installments on each monthly anniversary of May 25, 2017, subject to the reporting person's continued service with the Issuer. Read SEC document
April 27, 2017 Filed Jun 19, 2019 21:58 UTC	Savara Inc SVRA · Entity 4900	Exercise / conversionRestricted Stock Units · Derivative	1,142	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-19-017457 · doc4.xml · derivative · entry 7 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,142 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: The vesting of the restricted stock units occurred upon April 27, 2017 upon the consummation of the merger transaction contemplated by the Agreement and Plan of Merger, dated January 6, 2017, by and among Mast Therapeutics, Inc., Savara Inc., and Victoria Merger Corp. (the "Merger Agreement") but due to an administrative error was not reported at that time, and the shares were omitted from subsequent Form 4 filings. F2 · shares: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The amount reported reflects the 70-for-one reverse stock split implemented by the issuer on April 27, 2017. F3 · derivative.exercise_date: The restricted stock units vested in full on April 27, 2017, upon consummation of the merger transaction contemplated by the Merger Agreement. F3 · derivative.expiration_date: The restricted stock units vested in full on April 27, 2017, upon consummation of the merger transaction contemplated by the Merger Agreement. Read SEC document
April 27, 2017 Filed Jun 19, 2019 21:58 UTC	Savara Inc SVRA · Entity 4900	Exercise / conversionCommon Stock	1,142	$0.00	$0.00	Disclosure SEC source: 0000899243-19-017457 · doc4.xml · nonDerivative · entry 1 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,570 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: The vesting of the restricted stock units occurred upon April 27, 2017 upon the consummation of the merger transaction contemplated by the Agreement and Plan of Merger, dated January 6, 2017, by and among Mast Therapeutics, Inc., Savara Inc., and Victoria Merger Corp. (the "Merger Agreement") but due to an administrative error was not reported at that time, and the shares were omitted from subsequent Form 4 filings. Read SEC document
January 20, 2017 Filed Jan 23, 2017 22:22 UTC	Savara Inc MSTX · Entity 4900	GrantRestricted Stock Units · Derivative	79,962	$0.00	$0.00	Disclosure SEC source: 0001209191-17-005139 · doc4.xml · derivative · entry 1 RAMSAY DAVID A · CIK 0001283292 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,962 Underlying: Common Stock · 79,962 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vest in full upon consummation of the merger transaction contemplated by the Agreement and Plan of Merger, dated January 6, 2017, by and among the issuer, Savara Inc., and Victoria Merger Corp. (provided such event occurs on or before July 6, 2017). F2 · derivative.expiration_date: The restricted stock units vest in full upon consummation of the merger transaction contemplated by the Agreement and Plan of Merger, dated January 6, 2017, by and among the issuer, Savara Inc., and Victoria Merger Corp. (provided such event occurs on or before July 6, 2017). Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.